Tagged with M

Sanofi Aventis Malaysia Pharmaceutical Executive is a magazine about executives, their experience and their perspectives on the pharmaceutical industry. You have worked in Australia, Hong Kong and now you are the general manager of Malaysia, Singapore and Brunei. For the interest of our readers could you give an overview of what path you…

IMS Health Malaysia You spent most of your career in the pharmaceutical industry with Bristol Meyers Squibb and earlier on for NV Organon which you joined in 1998. In 2007 you left to join the world of consultancy, how useful was this insider knowledge to your work and what is it like now…

Alliance Pharma Plc Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we take a look back in time, can you explain what your drivers were to set up the company in 1998?…

Bristol-Myers Squibb UK Before joining Bristol-Myers Squibb (BMS), you have spent roughly twenty years with GSK. Can you describe the trajectory of your career and explain what attracted you in BMS? Before joining BMS 4 years ago and even before spending those twenty years with GSK, I had already worked for Sanofi-Aventis for…

Amgen B.V. You are still relatively new to the Netherlands having been here for one year. This must be a very insightful experience abroad. What were your initial expectations and first impressions when first starting here and how have they evolved over the course of your year as head of Amgen in…

Eli Lilly Malaysia You have spent much of your time working in the USA and came to Malaysia in 2008 as Country Manager. What were your expectations of Malaysia before you arrived and how have you enjoyed adapting to this ethnically diverse country? The opportunity has been enjoyable on a number of levels.…

Astellas Pharma Ltd. Astellas’s European headquarters is based in the UK. What does the UK market represent for the company? Speaking from a global perspective, 60% of Astellas’ business is based in Japan and Asia. Approximately 20% is in the U.S.; and approximately 20% is in Europe. So Europe still represents a vast—and…

Almirall UK The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall was founded in 1943 in Barcelona (Spain) and in 1944 it started its industrial and commercial activity. In the 60s…

Merck Sharp & Dohme Limited (MSD) You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the UK operations? As General Manager of the Merck/Schering-Plough Joint Venture in the US, I was responsible for the commercial operations…

Association of the British Pharmaceutical Industry (ABPI) Taking a look at a key achievement of the ABPI in recent years, we recognize the role you played in negotiating the revised PPRS that was put in place last year. How did the latest revision contribute to taking the research-based industry forward and what has been the impact of…

British Generic Manufacturers Association (BGMA) Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great emergence of the generic medicines, can you please explain the success of generic medicines in the UK? The important aspect about the UK, which…

Association of the British Pharmaceutical Industry (ABPI) What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If you look at the recent history of the pharmaceutical industry in the UK, perhaps one of the areas that we have been most successful…